Details

Autor(en) / Beteiligte

• Barua, Rajat S
• Rigotti, Nancy A
• Benowitz, Neal L
• Cummings, K Michael
• Jazayeri, Mohammad-Ali
• Morris, Pamela B
• Ratchford, Elizabeth V
• Sarna, Linda
• Stecker, Eric C
• Wiggins, Barbara S

Titel

2018 ACC Expert Consensus Decision Pathway on Tobacco Cessation Treatment: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents

Ist Teil von

• Journal of the American College of Cardiology, 2018-12, Vol.72 (25), p.3332-3365

Ort / Verlag

United States: Elsevier Limited

Erscheinungsjahr

2018

Quelle

MEDLINE

Beschreibungen/Notizen

• James L. Januzzi, Jr., MD, FACC Chair, ACC Task Force on Expert Consensus Decision Pathways1 Abstract Tobacco use, especially cigarette smoking, is a major risk factor for cardiovascular morbidity and mortality and is the leading preventable cause of death worldwide. Patients who use any tobacco product should receive clear advice to stop tobacco use and be offered a brief intervention that includes prescriptions for proven pharmacological smoking cessation aids and proactive connection to evidence-based behavioral support based in the healthcare system and/or the community. Clinically, tobacco smoking increases the risk of coronary heart disease (CHD) (including myocardial infarction [MI] and sudden death), cerebrovascular disease (stroke), peripheral artery disease, and abdominal aortic aneurysm (10,12,13). Experimental, epidemiological, and clinical studies demonstrate a nonlinear dose effect of cigarette smoke exposure on CV function and CVD such that a low level of cigarette use is associated with a disproportionately large excess in CV risk (10,11,20–22).